HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CAM JAPAN HDG

29.460

+0.1800.61%

Volume:4.09K

Turnover:120.35K

Market Cap:1.89B

PE:- -

High:29.540

Open:29.300

Low:29.300

Close:29.280

52wk High:30.853

52wk Low:18.224

Shares:64.20M

HK Float Shares:21.50M

Volume Ratio:0.14

T/O Rate:0.02%

Dividend:0.33

Dividend Rate:1.12%

ROE:--

ROA:--

PB:--

PE(LYR):- -

PS:- -

Loading ...

Overview Company News Filings

Press Release: Capital Group Canada Announces Cash Distribution for Capital Group Canada ETFs (CAPM, CAPW)

Press Release: Henlius Reports 2025 Results: Sustained Growth in Both Revenue and Profit, Advancing Innovation Validation and Global Operations

Press Release: Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST(TM) (etripamil) Nasal Spray for the Treatment of PSVT

Press Release: Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer

Press Release: The Ensign Group, Inc. Declares Quarterly Dividend of $0.0650 Per Share

Press Release: Antengene Announces 2025 Full-Year Results: First TCE Out-licensing Validates Platform Value and Marks Inflection Point Towards 2026 Profitability

Press Release: Samsonite Group S.A. Announces Results for the Year Ended December 31, 2025

Press Release: Solid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Press Release: electroCore Announces Full Year 2025 Financial Results and Organizational Changes

Press Release: CORVEX ANNOUNCES CLOSING OF ALL-STOCK MERGER

Press Release: Atossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two Experienced Biopharma Executives

Press Release: BrainsWay Completes Revenue-Based Milestone Investment into Axis Integrated Mental Health

Press Release: Pelthos Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results

Yomiuri: Toyota Tsusho Joins Rare Earth Development Project in Namibia

SoftBank Project Fee Slashed By Over 90% Amid Uncertainty Over $550 Billion US-Japan Trade Deal: Report

Benzinga_recent_news

Press Release: Alibaba Group Announces December Quarter 2025 Results

Press Release: Alvotech Q4 2025 and Full Year 2025 Financial Results

Press Release: ImmuCell Appoints Former Elanco Animal Health Board Member Kathy Turner to Board

Press Release: Hudson Technologies Announces Management Appointments to Strengthen Operations, Extend Market Reach and Accelerate Growth

Press Release: 4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/03160/news?page=10"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"03160","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"03160\",,,,,undefined,":{"symbol":"03160","market":"HK","secType":"STK","nameCN":"CAM JAPAN HDG","latestPrice":29.46,"timestamp":1775808112333,"preClose":29.28,"halted":0,"volume":4088,"delay":0,"changeRate":0.006147540983606548,"floatShares":21500000,"shares":64200000,"eps":0,"marketStatus":"Market Closed","change":0.18,"latestTime":"04-10 16:01:52","open":29.3,"high":29.54,"low":29.3,"amount":120348,"amplitude":0.008197,"askPrice":29.64,"askSize":1000,"bidPrice":29.44,"bidSize":200,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1776043800000},"marketStatusCode":7,"adr":0,"listingDate":1455724800000,"exchange":"SEHK","adjPreClose":29.28,"sharesOutstanding":32400000,"nav":29.5195,"aum":690018436.003,"dividendRate":0.011202,"bidAskSpread":0,"openAndCloseTimeList":[[1775784600000,1775793600000],[1775797200000,1775808000000]],"volumeRatio":0.14008347473514504,"lotSize":200,"spreadScale":3,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"03160\",,,,,undefined,":{"symbol":"03160","floatShares":21500000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.14008347473514504,"shares":64200000,"dividePrice":0.33,"high":29.54,"amplitude":0.008197,"preClose":29.28,"low":29.3,"week52Low":18.224,"pbRate":"--","week52High":30.853,"institutionHeld":0,"latestPrice":29.46,"committee":-0.666667,"eps":0,"divideRate":0.011202,"volume":4088,"delay":0,"ttmEps":0,"open":29.3,"prevYearClose":26.457,"prevWeekClose":28.8,"prevMonthClose":27.77,"prevQuarterClose":27.77,"fiveDayClose":27.77,"twentyDayClose":28.765,"sixtyDayClose":27.074},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/03160\",params:#limit:5,,,undefined,":[{"date":"2026-04-01","symbol":"03160","amount":0.15,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"HK","newRecordDate":"2026-04-02","defaultRemindTime":1775007000000,"name":"华夏日股对冲","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-04-10","payableDate":"2026-04-02","currency":"HKD","dateTimestamp":1774972800000,"payDate":"2026-04-10"},{"date":"2025-10-02","symbol":"03160","amount":0.18,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"HK","newRecordDate":"2025-10-03","defaultRemindTime":1759368600000,"name":"华夏日股对冲","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-10-10","payableDate":"2025-10-03","currency":"HKD","dateTimestamp":1759334400000,"payDate":"2025-10-10"},{"date":"2025-04-01","symbol":"03160","amount":0.15,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"HK","newRecordDate":"2025-04-02","defaultRemindTime":1743471000000,"name":"华夏日股对冲","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-08","payableDate":"2025-04-02","currency":"HKD","dateTimestamp":1743436800000,"payDate":"2025-04-08"},{"date":"2024-10-03","symbol":"03160","amount":0.15,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"HK","newRecordDate":"2024-10-04","defaultRemindTime":1727919000000,"name":"华夏日股对冲","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-10-10","payableDate":"2024-10-04","currency":"HKD","dateTimestamp":1727884800000,"payDate":"2024-10-10"},{"date":"2024-04-03","symbol":"03160","amount":0.12,"announcedDate":null,"type":"dividend","market":"HK","newRecordDate":"2024-04-05","defaultRemindTime":1712107800000,"name":"华夏日股对冲","recordDate":"2024-04-12","payableDate":"2024-04-05","currency":"HKD","dateTimestamp":1712073600000,"payDate":"2024-04-12"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"03160\",market:\"HK\",,,undefined,":[{"executeDate":"2017-03-30","recordDate":"2017-03-31","paymentDate":"2017-04-07","value":0.08,"currency":"HKD"},{"executeDate":"2017-09-28","recordDate":"2017-09-29","paymentDate":"2017-10-06","value":0.04,"currency":"HKD"},{"executeDate":"2018-03-28","recordDate":"2018-03-29","paymentDate":"2018-04-09","value":0.08,"currency":"HKD"},{"executeDate":"2018-10-02","recordDate":"2018-10-03","paymentDate":"2018-10-09","value":0.09,"currency":"HKD"},{"executeDate":"2019-04-01","recordDate":"2019-04-02","paymentDate":"2019-04-09","value":0.07,"currency":"HKD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"03160\",market:\"HK\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"03160\",pageSize:20,pageCount:10,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2621754456","title":"Press Release: Capital Group Canada Announces Cash Distribution for Capital Group Canada ETFs (CAPM, CAPW)","url":"https://stock-news.laohu8.com/highlight/detail?id=2621754456","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621754456?lang=en_us&edition=fundamental","pubTime":"2026-03-21 05:00","pubTimestamp":1774040400,"startTime":"0","endTime":"0","summary":"Details of the \"per unit\" distribution amounts are as follows:. Capital International Asset Management , Inc. is part of Capital Group, a global investment management firm originating in Los Angeles, California. As Capital Group approaches its 100 anniversary in 2031, its long-term strategy remains firmly rooted in its mission to improve people's lives through successful investing. With over 9,000 associates and 33 offices around the world, Capital Group manages US$3.2 trillion in assets for millions of wealth management and institutional clients around the world.*. Commissions, management fees and expenses all may be associated with investments in investment funds. Please read the prospectus before investing. Investment funds are not guaranteed, their values change frequently, and past performance may not be repeated.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","BK4604","03160","BK4555","TM","BK4099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620739551","title":"Press Release: Henlius Reports 2025 Results: Sustained Growth in Both Revenue and Profit, Advancing Innovation Validation and Global Operations","url":"https://stock-news.laohu8.com/highlight/detail?id=2620739551","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620739551?lang=en_us&edition=fundamental","pubTime":"2026-03-20 21:03","pubTimestamp":1774011780,"startTime":"0","endTime":"0","summary":"SHANGHAI, March 20, 2026 /PRNewswire/ -- Henlius  today announced its annual results for the year ended December 31, 2025. During the reporting period, the Company recorded revenue of RMB 6.6666 billion, representing a year-on-year increase of 16.5%, and net profit of RMB 0.8270 billion. Total R&D investment reached RMB 2.4919 billion, an increase of 35.4%. Amid continued investment in innovation, pre-R&D profit grew to RMB 2.3425 billion, up 26.2% year-on-year. This marks the third consecutive year of profitability and sustained growth of revenue since the Company first achieved full-year profitability in 2023, demonstrating resilient and sustainable profitability, alongside high-quality growth.The Company's flagship product, serplulimab , continued to deliver global commercial momentum. During the reporting period, it recorded global sales revenue of RMB 1.4926 billion, representing a year-on-year increase of 13.7%. It received approvals in 2025 in Europe and multiple emerging market","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4099","HK0000306685.HKD","HK0000320223.HKD","BK4081","BK4588","IND","TM","BK4585","BK4232","BK1161","EC","BK4555","EMA","HK0000320264.USD","MSS","02696","03160","R","BK4022","BK4201","HK0000306701.USD","BK4113","HK0000165453.HKD","BK4604"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620780220","title":"Press Release: Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST(TM) (etripamil) Nasal Spray for the Treatment of PSVT","url":"https://stock-news.laohu8.com/highlight/detail?id=2620780220","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620780220?lang=en_us&edition=fundamental","pubTime":"2026-03-20 19:12","pubTimestamp":1774005120,"startTime":"0","endTime":"0","summary":"-- FDA approval of CARDAMYST represents first new option in 30 years for the. -- Participants using CARDAMYST in clinical studies were 2x more likely to. convert symptomatic PSVT to sinus rhythm and did so more than 3x faster. -- CARDAMYST launch execution on track with positive initial engagement in. -- $200 million pro forma cash supports strong launch and operating runway. into late 2027; includes $106 million of cash at year-end and net. MONTREAL and CHARLOTTE, N.C., March 20, 2026  -- Milestone Pharmaceuticals Inc. , a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today reported financial results for the fourth quarter and full year ending December 31, 2025, and provided corporate and regulatory updates. The main drivers of the fourth quarter and full year 2025 activities include the U.S. Food and Drug Administration  approval of CARDAMYST  nasal spray for the conversion of acute symptomatic episodes of paroxysma","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4215","EMA","BK4022","LABU","BK4099","MIST","BK4604","TM","03160","BK4081","BK4585","BK4588","R","BK4007","BK4555","BK4232","MAA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620780623","title":"Press Release: Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2620780623","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620780623?lang=en_us&edition=fundamental","pubTime":"2026-03-20 19:00","pubTimestamp":1774004400,"startTime":"0","endTime":"0","summary":"-- Thomas A. Zalewski, a Partner at Day Pitney LLP, appointed Chief Legal. Officer and Chief Compliance Officer effective April 2, 2026. -- Lori J. Braender to remain in a non-executive role as Corporate Secretary. after nearly eight years as Chief Legal Officer, Chief Compliance Officer. Mr. Zalewski joins Aquestive as Chief Legal Officer and Chief Compliance Officer effective April 2, 2026. Mr. Zalewski is a Partner at Day Pitney LLP, where he serves as Chair of the firm's Healthcare and Life Sciences practice. He has considerable experience advising life sciences, technology, and healthcare companies on a broad range of strategic and commercial matters, including mergers and acquisitions, licensing and intellectual property transactions, corporate governance, and regulatory matters. Mr. Zalewski has also served as outside general counsel to emerging and middle-market companie","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4604","AQST","03160","TM","CDMO","LENZ","BK4539","BK4099","BK4139","BK4585","BK4588","BK4232","BK4007","BK4555","BK4022","R"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620828237","title":"Press Release: The Ensign Group, Inc. Declares Quarterly Dividend of $0.0650 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2620828237","media":"Dow Jones","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620828237?lang=en_us&edition=fundamental","pubTime":"2026-03-20 18:00","pubTimestamp":1774000800,"startTime":"0","endTime":"0","summary":"SAN JUAN CAPISTRANO, Calif., March 20, 2026  -- The Ensign Group, Inc. , the parent company of the Ensign group of companies, which invest in and provide skilled nursing and senior living services, physical, occupational and speech therapies, other rehabilitative and healthcare services, and real estate, announced today that it has declared a quarterly cash dividend of $0.0650 per share of Ensign common stock, payable on or before April 30, 2026, to shareholders of record as of March 31, 2026.Ensign has been a dividend-paying company since 2002.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","03160","BK4185","BK4604","BK4555","ENSG","TM","BK4099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620789015","title":"Press Release: Antengene Announces 2025 Full-Year Results: First TCE Out-licensing Validates Platform Value and Marks Inflection Point Towards 2026 Profitability","url":"https://stock-news.laohu8.com/highlight/detail?id=2620789015","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620789015?lang=en_us&edition=fundamental","pubTime":"2026-03-20 17:06","pubTimestamp":1773997560,"startTime":"0","endTime":"0","summary":"SHANGHAI and HONG KONG, March 20, 2026 /PRNewswire/ -- Antengene Corporation Limited  today announced its full-year results for the period ending December 31, 2025, and provided an update on recent business highlights and strategic progress.Looking ahead, we will continue to advance our clinical pipeline with disciplined cost control while expanding our innovation capabilities across new and emerging scientific platforms. With multiple novel modalities in development, we believe we are well positioned to further strengthen our R&D engine and support sustainable long-term growth.\"","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B7SZL793.SGD","BK4585","IE00B66KJ199.SGD","BK4588","BK4232","BK4604","BK4187","R","LU0963586101.USD","USD","06996","BK1191","CPI","BK4555","BK1583","BK4099","BK4022","03160","CRS","LU2065731478.USD","BK4006","IE00B19Z4B17.USD","IE0031619046.USD","BK1574","TM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620277490","title":"Press Release: Samsonite Group S.A. Announces Results for the Year Ended December 31, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2620277490","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620277490?lang=en_us&edition=fundamental","pubTime":"2026-03-20 07:45","pubTimestamp":1773963900,"startTime":"0","endTime":"0","summary":"Consolidated net sales were US$963.3 million, an increase of 2.2%  year-over-year; and a sequential improvement compared to a year-over-year decrease of 0.6%   in the third quarter of 2025.Achieved gross profit margin of 60.3% and adjusted EBITDA margin of 20.3%; and generated adjusted free cash flow of US$170.0 million, up 25.7% year-over-year.Delivered gross profit margin of 59.6% and adjusted EBITDA margin of 17.3%; Generated adjusted free cash flow of US$246.3 million; and returned approximately US$192.9 million to shareholders during the year.MANSFIELD, Mass. and HONG KONG, March 19, 2026 /PRNewswire/ -- Samsonite Group S.A. , the world's best-known and largest travel luggage company and a leader in global lifestyle bags, today published its final results for the year ended December 31, 2025.Unless otherwise stated, all net sales growth rates are presented on a constant currency basis.\"Our constant currency net sales growth in the fourth quarter of 2025 was driven by a 3.6% increa","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03160","BK4588","LU1166156734.SGD","LU2065171402.SGD","BK4099","LU0607220059.USD","BK4555","LU2065171311.SGD","LU0251143458.SGD","BK4585","SG9999011746.SGD","LU2065169927.USD","LU1880383366.USD","LU0823040885.USD","SG9999004303.SGD","SGXZ23171101.USD","LU0264606111.USD","SG9999004311.SGD","TM","LU0702159343.USD","BK1500","LU0149534421.HKD","LU2065170008.USD","BK1577","LU0702159699.USD","BK4604","LU0572940350.SGD","01910","BK1602","LU0572939691.SGD","BK1227"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620741276","title":"Press Release: Solid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2620741276","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620741276?lang=en_us&edition=fundamental","pubTime":"2026-03-20 04:12","pubTimestamp":1773951120,"startTime":"0","endTime":"0","summary":"- Company anticipates dosing the first participant in the Phase 3 IMPACT DUCHENNE trial in April 2026; additional meetings planned with FDA in H1 2026 for guidance on a potential accelerated approval pathway for SGT-003 -. - Friedreich's Ataxia : First participant dosed in the Phase 1b FALCON trial; SGT-212 has been well tolerated with no treatment-related adverse events -. - CPVT : Clinical sites activated for Phase 1b ARTEMIS first-in-human clinical trial evaluating SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia ; first participant dosing expected in Q2 2026 -. -- SGT-003 continued to be generally well tolerated in the 41 participants","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","SLDB","BK4588","BK4585","BK4130","BK4139","BK4604","FA","TM","03160","BK4539","BK4555","BK4099"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620276497","title":"Press Release: electroCore Announces Full Year 2025 Financial Results and Organizational Changes","url":"https://stock-news.laohu8.com/highlight/detail?id=2620276497","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620276497?lang=en_us&edition=fundamental","pubTime":"2026-03-20 04:05","pubTimestamp":1773950700,"startTime":"0","endTime":"0","summary":"Record full year 2025 net sales of $32.0, an increase of 27% over $25.2 million for the full year 2024 driven by 25% annual growth in our U.S. prescription business and 97% increase in general wellness sales. Announces the retirement of Dan Goldberger as Chief Executive Officer in addition to other key executive management changes. Company to host a conference call and webcast today, March 19, 2026, at 4:30pm EDT. ROCKAWAY, N.J., March 19, 2026  -- electroCore, Inc.  , a bioelectronic technology company, today announced full year 2025 financial results.-- Reported record full year of 2025 revenue of $32.0 million, an increase. of approximately 27% over full year of 2024.-- Cash, cash equivalents, and marketable securities  of $11.6. -- Full year 2026 revenue guidance of approximately 30% annual growth.April 1, 2026, and Joshua Lev will be taking on the role of interim. Full Year 2025 Financial Results and 2026 Select Guidance","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ECOR","BK4022","BK4099","BK4082","BK4604","TM","03160","BK4585","BK4588","R","BK4555","BK4232"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620600240","title":"Press Release: CORVEX ANNOUNCES CLOSING OF ALL-STOCK MERGER","url":"https://stock-news.laohu8.com/highlight/detail?id=2620600240","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620600240?lang=en_us&edition=fundamental","pubTime":"2026-03-19 20:15","pubTimestamp":1773922500,"startTime":"0","endTime":"0","summary":"-- Upon the 2026 Stockholders' Meeting to be held in May 2026, subject to. approval by the stockholders and board of directors of the Company,Corvex will be led by Jay Crystal and Seth Demsey as Co-Chief Executive. -- Movano Inc. to be renamed Corvex, Inc. and continue to trade on The. Nasdaq Stock Market under the symbol \"MOVE\" after the Merger.-- Prior to the Merger, Corvex, together with Movano, raised $40.2 million. Pursuant to the Merger Agreement, the Company today also announced a stock dividend payable to holders of outstanding shares of Movano's common stock, par value $0.0001 per share  of 0.358 share of Common Stock for every share of outstanding Common Stock . The Stock Dividend will be issuable to stockholders of record at the close of business on March 30, 2026 and will be distributed and allocated on April 6, 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4543","BK4099","LU2355687059.USD","LU0985320562.USD","LU1571399168.USD","BK4585","BK4528","BK4107","BK4551","TM","BK4604","BK4587","MOVE","03160","AIYY","BK4023","BK4588","BK4170","BK4555","AI","LU1699723380.USD","BK4533","ALL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620247781","title":"Press Release: Atossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two Experienced Biopharma Executives","url":"https://stock-news.laohu8.com/highlight/detail?id=2620247781","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620247781?lang=en_us&edition=fundamental","pubTime":"2026-03-19 20:00","pubTimestamp":1773921600,"startTime":"0","endTime":"0","summary":"SEATTLE, March 19, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc.  , a clinical-stage biopharmaceutical company developing novel therapies in oncology and other rare diseases, today announces the engagement of Kathy Puyana Theall, M.D., as Medical Director - Breast Oncology, and Adebola Giwa, M.D., as Medical Director - Rare Diseases.  The addition of these two highly experienced physicians and clinical leaders meaningfully strengthens Atossa's ability to execute on its -endoxifen development strategy across both breast cancer and rare disease programs, including McCune-Albright syndrome  and Duchenne Muscular Dystrophy , as the Company advances toward key clinical and regulatory milestones.\"Atossa is at an important stage of growth,\" said Dr. Theall. \"The company's commitment to advancing innovative therapies in breast cancer strongly aligns with my experience and passion, and I look for","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["Z","BK4086","LU2413665964.HKD","LU1596574779.USD","LU2413666004.HKD","BK4585","TM","BK4555","BK4588","LU1620156213.USD","LU1165135440.EUR","BK4099","LU0170899867.USD","BK4007","BK4139","BK4022","LENZ","LU1620156130.USD","BK4079","LU1543694498.USD","R","BK4539","03160","LU1721427968.SGD","BK4551","SG9999001440.SGD","BK4232","BK4120","BK4604","MAS","BK4548","TISI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620242641","title":"Press Release: BrainsWay Completes Revenue-Based Milestone Investment into Axis Integrated Mental Health","url":"https://stock-news.laohu8.com/highlight/detail?id=2620242641","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620242641?lang=en_us&edition=fundamental","pubTime":"2026-03-19 19:30","pubTimestamp":1773919800,"startTime":"0","endTime":"0","summary":"BURLINGTON, Mass. and JERUSALEM, March 19, 2026  -- BrainsWay Ltd.  , a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it has completed a $1 million milestone-based investment in Axis Management Company, Inc. , a management services organization servicing several mental health clinics in Colorado. The investment was made following Axis's achievement of a predefined revenue performance milestone under the terms of the two companies' August 2025 strategic equity financing agreement.\"We are excited for the Axis team and their early success in executing a successful growth strategy since our original $2.3 million equity investment. Their rapid achievement of the revenue milestone underscores this program's ability to identify strong networks such as Axis that can deploy capital effectively to drive growth within the market and increase access to care,\" said Hadar Levy, Chief Executive Officer of BrainsWay.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4604","R","BK4099","BK4588","BWAY","BK4232","BK4082","TM","BK4585","03160","BK4022","BK4555"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620249476","title":"Press Release: Pelthos Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2620249476","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620249476?lang=en_us&edition=fundamental","pubTime":"2026-03-19 18:30","pubTimestamp":1773916200,"startTime":"0","endTime":"0","summary":"ZELSUVMI net product revenue grew 28% Quarter over Quarter to $9.1 million, bringing total ZELSUVMI net product revenue to $16.2 million, for the period from the launch in July 2025 through December 31, 2025. Total revenue including licensing revenue was $16.8 million for 2025.8,948 ZELSUVMI units prescribed by 2,712 unique prescribers for fiscal year 2025, with a 129% quarter over quarter increase in units dispensed, rising from 2,716 units in the third quarter of 2025 to 6,232 units in the fourth quarter of 2025.Management will host a conference call today at 8:00 a.m. EDT. -- ZELSUVMI, the first at home FDA-approved treatment for molluscum. contagiosum , a highly contagious viral skin infection that largely. afflicts children, was launched in July 2025 and generated $16.2 million. in net sales in the first two quarters of commercial operations,-- From the launch of ZELSUVMI in July 2025 through December 31, 2025, 8,948. units of ZELSUVMI were dispensed and were written by 2,712 uniq","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","03160","BK4604","BK4232","BK4555","TM","BK4099","BK4585","R","BK4022","BK4588","LENZ","PTHS","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620246607","title":"Yomiuri: Toyota Tsusho Joins Rare Earth Development Project in Namibia","url":"https://stock-news.laohu8.com/highlight/detail?id=2620246607","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620246607?lang=en_us&edition=fundamental","pubTime":"2026-03-19 17:56","pubTimestamp":1773914160,"startTime":"0","endTime":"0","summary":"Toyota Tsusho Corp. will take part in a rare earth development project in Namibia, the major Japanese trading house announced on Wednesday.Research in the country by the Japan Organization for Metals and Energy Security  confirmed the presence of rare metal elements such as dysprosium, which are used in electric vehicle motors.Toyota Tsusho aims to make a decision on commercialization within fiscal 2026, which starts in April.JOGMEC has been developing a mine in northern Namibia together with a Canadian company since 2020. Toyota Tsusho will take over part of JOGMEC's involvement in the project, with an aim to supply rare earth elements to Japan.China dominates mining and refining of critical minerals, including rare earth elements, making diversifying supply sources a challenge for Japan from the perspective of economic security.This article is from The Yomiuri Shimbun. Neither Dow Jones Newswires, MarketWatch, Barron's nor The Wall Street Journal were involved in the creation of this","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4604","03160","TM","BK4555","BK4099","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620245250","title":"SoftBank Project Fee Slashed By Over 90% Amid Uncertainty Over $550 Billion US-Japan Trade Deal: Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2620245250","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620245250?lang=en_us&edition=fundamental","pubTime":"2026-03-19 17:32","pubTimestamp":1773912720,"startTime":"0","endTime":"0","summary":"The anticipated ¥1 trillion ($6.3 billion) fee for SoftBank from a U.S.-Japan project has been reduced by over 90% due to intervention from Tokyo officials amid growing concerns over the $550 billion joint investment plan between the U.S. and Japan.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/19/Taipei-City--Taiwan---Jun-22--2019masayo.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/19/Taipei-City--Taiwan---Jun-22--2019masayo.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/asia/26/03/51347609/softbank-project-fee-slashed-by-over-90-amid-uncertainty-over-550-billion-us-japan-trade-deal-report","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/asia/26/03/51347609/softbank-project-fee-slashed-by-over-90-amid-uncertainty-over-550-billion-us-japan-trade-deal-report","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4132","SFTBY","03160"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620587245","title":"Press Release: Alibaba Group Announces December Quarter 2025 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2620587245","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620587245?lang=en_us&edition=fundamental","pubTime":"2026-03-19 17:30","pubTimestamp":1773912600,"startTime":"0","endTime":"0","summary":"Alibaba Group Holding Limited  today announced its financial results for the quarter ended December 31, 2025.\"The rapid growth of AI + Cloud businesses in recent quarters gives us confidence to scale investments, further strengthening our full-stack AI capabilities. In consumption, our quick commerce business continues to scale while unit economics improved steadily. Our strong liquidity position and resilient cash generation provide a solid foundation to support sustained strategic investment,\" said Toby Xu, Chief Financial Officer of Alibaba Group.--  Revenue was RMB284,843 million , an increase of 2%. year-over-year. Excluding revenue from the disposed businesses of Sun Art. and Intime, revenue on a like-for-like basis would have grown by 9%. --  Income from operations was RMB10,645 million , a. decrease of 74% year-over-year, primarily due to the decrease in adjusted. EBITA. Adjusted EBITA, a non-GAAP measurement, decreased 57%. attributable to the investment in quick commerce, use","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ffc2b7b63af3122f7c88c1540e0880fd","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0651946864.USD","LU2488822045.USD","LU0244354667.USD","LU1008478684.HKD","LU2257852520.SGD","LU1568876335.HKD","LU0149721374.USD","LU0143863784.USD","LU0128522157.USD","LU0359202008.SGD","LU1769817096.USD","LU1366334578.USD","89988","LU0516422440.USD","LU0873338254.USD","SG9999000327.SGD","LU2125910849.SGD","LU0608807946.USD","LU0039217434.USD","BK4099","LU1188198961.HKD","BK4533","IE00B0JY6N72.USD","LU0865486749.SGD","IE00BZ08YR35.GBP","LU0163747925.USD","LU0651947912.USD","LU0469268626.HKD","LU3063872942.SGD","LU0359201612.USD","LU0661504455.SGD","LU0061477393.USD","LU1048484197.HKD","LU0310800965.SGD","LU0593848301.USD","LU2476274308.USD","BK1591","BK4531","LU0345776255.USD","LU0588545730.USD","LU0359201885.HKD","LU1328615791.USD","LU0196878994.USD","LU0431992006.USD","LU0828237940.HKD","LU0054237671.USD","SGXZ62798434.SGD","LU0672654166.SGD","LU0128525689.USD","LU0543330483.HKD","LU0052756011.USD","LU1201861165.SGD","BK1588","LU0650527681.SGD","BK4122","BK1610","BK4565","LU0516422366.SGD","LU1196710864.SGD","BK4558","LU1224444064.USD","LU1504937902.USD","BK1608","LU0737861772.HKD","BK1501","LU1044876610.USD","LU1044875133.USD","LU0117844026.USD","SG9999014674.SGD","IE0008368304.USD","BK1502","BK1615","LU0164865239.USD","LU0197773160.USD","LU0862451753.SGD","SG9999001226.SGD","LU0499858602.USD","IE0034224299.USD","IE00BZ08YS42.EUR","LU0516423091.SGD","LU0823397285.USD","LU0210526637.USD","LU0828237510.HKD","LU0648000940.SGD","LU0456846285.SGD","HK0000320264.USD","SG9999004220.SGD","SG9999000459.SGD","LU0293314216.USD","LU0348827113.USD","LU0516423174.USD","LU0048597586.USD","LU1023057109.AUD","LU1439103000.SGD","LU1807302812.USD","LU1831875114.USD","LU1152091168.USD","LU2039709279.SGD","LU0417516738.SGD","LU0149534421.HKD","LU0264606111.USD","LU2476274720.SGD","LU0011963245.USD","LU1868838027.USD","LU2097828631.EUR","LU0456827905.SGD","LU1568876251.USD","LU1720051108.HKD","LU0572944931.SGD","LU0417516571.SGD","LU2449936058.SGD","BK1517","LU0540923850.HKD","LU2097828474.EUR","BK4232","LU1808992512.USD","LU0543330566.HKD","LU0130518102.USD","LU0823039010.USD","LU0169518387.USD","LU0577902371.SGD","LU1794554557.SGD","LU1813983027.USD","LU0488056044.USD","BK4023","LU2226246903.HKD","LU2148611432.USD","LU0630378692.HKD","LU0588545904.SGD","LU1051768304.USD","LU0315178854.USD","LU1323998911.USD","LU0634319403.HKD","LU2097828557.USD","BK4503","LU0762542818.HKD","LU0831103253.SGD","SG9999001689.USD","LU0449515922.USD","LU1046421795.USD","LU0049853897.USD","LU0577902454.USD","LU0251144936.SGD","LU1548497426.USD","LU0327786744.USD","LU0553294199.USD","LU2097829019.USD","LU0164872284.USD","BK4588","LU0477156797.USD","BK4548","LU1152091754.HKD","LU0348788117.USD","LU0630378429.USD","LU1048596156.SGD","LU0640798160.USD","LU0370786039.SGD","LU1105468828.SGD","LU0197773673.USD","LU0791590937.USD","LU0949170772.SGD","LU0320764599.SGD","LU1880398554.USD","LU1981816686.USD","LU0588546209.SGD","LU0128522744.USD","BK4538","LU0737861699.HKD","BK4524","LU0326950275.SGD","LU0348816934.USD","LU1515016050.SGD","LU1316542783.SGD","BK4528","LU0823041008.USD","LU1880383440.USD","LU1242518857.USD","IE0032431581.USD","LU0043850808.USD","LU1282651121.HKD","LU0708995153.HKD","BK4579","IE00BF5LJ272.USD","SGXZ90724238.SGD","LU0455707207.USD","BK4581","LU2399975544.HKD","LU1051769294.HKD","LU1282651048.USD","BK4614","BK1521","LU0675040207.SGD","LU0254981946.USD","SG9999001093.SGD","BK4527","LU0320764755.SGD","LU0348784397.USD","LU0541501648.USD","LU0106959298.USD","LU1961090484.USD","SG9999006514.SGD","LU0127658192.USD","LU0106259558.USD","LU0577902298.EUR","LU0287142896.SGD","LU1688375341.USD","LU0823038988.USD","LU0577902538.SGD","LU0441854154.USD","BK1575","LU0823397103.USD","IE00BMPRXR70.SGD","LU0577902611.USD","LU2778985437.USD","LU1956131251.USD","LU1993786604.SGD","LU0886674414.USD","LU0048388663.USD","BK4587","LU0708995583.HKD","LU0117841782.USD","LU0048580855.USD","LU0307460666.USD","LU0607220059.USD","LU1770036033.HKD","BK4554","LU0130103400.USD","LU0329678170.USD","LU0594300179.USD","LU2152927971.USD","LU2242644610.SGD","LU0165289439.USD","LU0384037296.USD","LU1242518931.SGD","LU0054450605.USD","LU0856984785.SGD","LU0229945570.USD","LU0501845795.SGD","BK4535","LU0235996351.USD","LU0259732245.USD","LU0214875030.USD","09988","LU1868837565.USD","LU0396098781.USD","LU0823413660.USD","LU0918141705.HKD","AIYY","LU0819121731.USD","LU0821914370.USD","IE0003895053.USD","SG9999001051.SGD","LU1366334651.USD","03160","IE00B5MMRT66.SGD","SG9999002828.SGD","LU2087589342.USD","LU0531970944.HKD","LU1211504680.USD","LU0210527791.USD","LU0251143458.SGD","LU2357305700.SGD","BK4220","LU1719994722.HKD","LU0784639295.USD","LU0819123356.HKD","LU1048588211.SGD","LU0862451837.USD","LU1481107354.HKD","LU0868486357.SGD","LU0329678337.USD","LU0051755006.USD","LU0823413587.USD","LU0029875118.USD","LU0608807433.USD","BK4555","BK4502","IE00B543WZ88.USD","LU0047713382.USD","BK4534","LU0320764243.SGD","LU1769817179.HKD","LU0417516902.SGD","LU0823040885.USD","LU0738911758.USD","BABW","LU1115378108.SGD","LU0463099449.HKD","HBBD.SI","BABX","LU0067412154.USD","LU0140636845.USD","LU0348783662.USD","LU0096374516.USD","LU0572940350.SGD","LU0541502299.USD","LU0871576103.HKD","LU1282649810.SGD","SG9999002463.SGD","LU0261947096.USD","HK0000306685.HKD","BABO","LU1282648689.USD","LU0164880469.USD","LU0797268264.HKD","LU0231483743.USD","LU1642822792.SGD","LU0181495838.USD","LU0228367735.SGD","BK4505","LU0762540952.USD","KBAB","LU0315179316.USD","LU0700851271.USD","LU1328277881.USD","LU0823426480.USD","LU0348735423.USD","LU1046422090.SGD","LU0605514214.HKD","LU0348805143.USD","BK1249","BK1584","BK4607","LU0880133367.SGD","HK0000320223.HKD","LU0348825331.USD","SG9999002562.SGD","BK1586","LU0132412106.USD","LU1267930227.SGD","LU0348814723.USD","LU2125910500.SGD","BBYY","IE00B3M56506.USD","LU2097828714.EUR","BK4543","LU0084288322.USD","LU1003077747.HKD","LU0449509016.USD","IE00B0169N27.USD","LU0052750758.USD","LU0831093199.SGD","LU1823568750.SGD","LU1235294995.USD","LU0228659784.USD","LU0143863198.USD","HK0000306701.USD","LU0261950983.USD","LU0545039389.USD","LU1960683339.HKD","LU0345775950.USD","LU0762541174.USD","LU0516422952.EUR","LU0918141887.USD","BK4526","LU1770034418.SGD","LU1303224171.USD","LU0328353924.USD","LU1720051017.SGD","BK4022","IE00BZ08YT58.USD","LU1044874839.SGD","LU0898667661.SGD","LU0648948544.HKD","LU0642271901.SGD","LU0890818403.SGD","LU0823426308.USD","LU2293587155.HKD","LU1224709979.USD","LU0589944569.HKD","LU1282649067.USD","BK1618","SGXZ86797644.SGD","SG9999006597.SGD","LU1810669033.SGD","BK4585","LU1655091459.SGD","LU1880383366.USD","LU1720050803.USD","IE00BFMHRM44.USD","LU0072913022.USD","BK4504","LU1880398471.USD","LU0348783233.USD","LU0979878070.USD","LU1251922891.USD","LU0211977185.USD","LU0456842615.SGD","BABA","LU0594300419.USD","LU0561508036.HKD","LU2045819591.USD","LU2097828805.USD","LU0791591158.USD","LU0029874905.USD","LU0531971595.HKD","LU0502904849.HKD","LU0072462343.USD","IE00BPRC5H50.USD","LU0499858438.USD","LU0106252389.USD","BK4551","LU1282649141.HKD","LU0572939691.SGD","LU0611395673.USD","IE00BMPRXN33.USD","BK1142","BK4575","BK4604","SG9999001903.USD","BABU","LU0314109678.HKD","LU0173614495.USD","LU0588545490.SGD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2620649293","title":"Press Release: Alvotech Q4 2025 and Full Year 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2620649293","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620649293?lang=en_us&edition=fundamental","pubTime":"2026-03-19 06:15","pubTimestamp":1773872100,"startTime":"0","endTime":"0","summary":"-- Total revenues1 were $173 million, up 13% Year-on-Year . -- Adjusted EBITDA1 was $69 million with Gross Margin at 66%. -- AVT05 was approved as a biosimilar to Simponi in the UK and European. -- AVT03 was approved as a biosimilar to Prolia and Xgeva in the EEA. -- The EMA accepted for review a marketing application for AVT23,-- After the end of the quarter, Alvotech entered into supply and. -- The cash balance on December 31, 2025, was $172 million. -- Second biosimilar in the US, Selarsdi referencing Stelara launched. -- Three new biosimilars were approved in multiple markets, including the UK,-- Alvotech acquired Xbrane's R&D organization in Sweden and Ivers-Lee Group. -- Linda Jonsdottir was appointed Chief Financial Officer, Dr. Balaji V.Prasad was appointed Chief Strategy Officer, while Joseph McClellan. transitioned into the role of Chief Operating Officer and Anthony Maffia. into the role of Chief Regulatory and Quality Officer. Comments by Chairman of the Board and Outgoing ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1770036033.HKD","SG9999014484.SGD","SG9999002414.USD","LU0264606111.USD","LU0979878070.USD","LU1048588211.SGD","LU0572940350.SGD","BK4585","LU0823039010.USD","BK4551","LU2152927971.USD","BK4097","LU2125910849.SGD","LU0251143029.SGD","BK4085","BK4604","LU1839390173.USD","SG9999006266.SGD","LU0348788117.USD","LU0289960550.SGD","IE0031814969.USD","LU0589944569.HKD","SG9999004360.SGD","BK4232","LU2008162690.USD","LU0516423174.USD","LU2065169927.USD","LU0572939691.SGD","LU2238330802.EUR","LU1861220207.SGD","SG9999001135.SGD","LU0175139822.USD","IE0001KFT4U8.USD","LU2065170008.USD","LU0441851309.USD","LU2543165471.USD","LU0072462343.USD","LU0499858438.USD","LU0823038988.USD","LU0048573645.USD","BK4099","SG9999002620.SGD","LU0516422366.SGD","LU0499858602.USD","LU2065171311.SGD","BK4503","LU0345776255.USD","LU1861217088.USD","LU0516422952.EUR","03160","BK4139","BK4022","LU1242518931.SGD","BK4554","LU2125910500.SGD","SG9999013478.USD","ALVO","SG9999005177.SGD","LU0261945553.USD","BK4220","BK4566","LU2065171402.SGD","SG9999002604.SGD","IE00BD6J9T35.USD","LU0516422440.USD","LU0532188223.SGD","BK4535","LU0516423091.SGD","SG9999002679.SGD","BK4555","SG9999013460.SGD","LU0210637038.USD","LU1242518857.USD","LU2360107671.USD","SG9999014492.USD","SG9999002406.SGD","SGXZ58947870.SGD","BK4588","LU2045819591.USD","LU2177674079.SGD","SG9999013486.USD","BK4581","LU0345775950.USD","BK4548","LU0737861269.HKD","IE0034224299.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620264764","title":"Press Release: ImmuCell Appoints Former Elanco Animal Health Board Member Kathy Turner to Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2620264764","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620264764?lang=en_us&edition=fundamental","pubTime":"2026-03-19 04:05","pubTimestamp":1773864300,"startTime":"0","endTime":"0","summary":"PORTLAND, Maine, March 18, 2026  -- ImmuCell Corporation  , an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity, today announced that Kathy Turner has been appointed to its Board of Directors, effective April 1, 2026. Ms. Turner replaces Steven Rosgen, who is retiring from the Board after serving since January 2018. Upon joining the Board, Ms. Turner will serve as Chair of the Compensation and Stock Option Committee and as a member of the Audit Committee.Ms. Turner brings more than three decades of commercial executive leadership experience in global healthcare and animal health markets and previously served on the Board of Directors of Elanco Animal Health, a leading animal health company. From 2014 to 2023, she held senior leadership roles at IDEXX Laboratories, including most recently serving as Chief Marketing Officer and Senior Vice President of International Operations, where she contributed to sustained doub","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03160","BK4604","BK4232","BK4555","TM","BK4099","BK4585","ICCC","R","BK4022","BK4588","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620264752","title":"Press Release: Hudson Technologies Announces Management Appointments to Strengthen Operations, Extend Market Reach and Accelerate Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2620264752","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620264752?lang=en_us&edition=fundamental","pubTime":"2026-03-19 04:05","pubTimestamp":1773864300,"startTime":"0","endTime":"0","summary":"-- ROB STOODY PROMOTED TO SENIOR VICE PRESIDENT, OPERATIONS. \"As we begin to move through 2026, we have restructured our senior management team with the goal of more effectively leveraging our industry-leading sales and service capabilities. The HVAC industry requires a multitude of products and services to keep cooling systems online, and we have elevated and expanded our team to ensure we are employing the best go-to-market and customer service strategies to further our leadership position while driving profitable growth,\" stated Ken Gaglione, President and Chief Executive Officer of Hudson Technologies.As part of the Company's management restructuring, Kirk Reimer will take on the expanded role of Vice President, Sales and Marketing where he will oversee refri","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4099","IE00B66KJ199.SGD","IE00B7SZL793.SGD","BK4588","TM","DLA","BK4585","BK4232","IE0031619046.USD","HDSN","BK4104","HUDAU","BK4555","IE00B19Z4B17.USD","03160","R","BK4022","AAQC","BK4202","BK4604"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620264721","title":"Press Release: 4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2620264721","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620264721?lang=en_us&edition=fundamental","pubTime":"2026-03-19 04:05","pubTimestamp":1773864300,"startTime":"0","endTime":"0","summary":"-- Completed enrollment in 4D-150 4FRONT-1 wet AMD Phase 3 trial within. approximately 11 months, ahead of initial projections and reflecting. strong interest from investigators and patients; topline data expected in. -- PRISM wet AMD Phase 2b 2-year data expected in mid-2026 and SPECTRA DME. -- 4D-150 DME global Phase 3 trial initiation expected in Q3 2026. -- $514 million in cash, cash equivalents and marketable securities expected. to fund current operating plan into second half of 2028. EMERYVILLE, Calif., March 18, 2026  -- 4D Molecular Therapeutics , a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today reported full year 2025 financial results, provided operational highlights and outlined expected upcoming milestones.-- 4DMT retains full development and commercialization rights for","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0823421333.USD","LU1861558580.USD","BK4612","LU0109392836.USD","AMDD","LU0889565833.HKD","BK4532","LU0823434583.USD","BK4543","LU1242518857.USD","LU1852331112.SGD","BK4139","BK4555","AMDL","03160","LU0719512351.SGD","LU2089985449.USD","BK4093","BK4566","LU0979878070.USD","LU2355687059.USD","LU2458330169.SGD","LU1951198990.SGD","LU1316542783.SGD","BK4141","BK4534","LU2458330243.SGD","LU2054465674.USD","LU1923623000.USD","BK4614","AMDU","LU1951200564.SGD","BK4512","IE00BMPRXR70.SGD","LU0823434740.USD","IE00BMPRXN33.USD","AMUU","BK4529","BK4554","LU1861559042.SGD","LU0823421416.USD","BK4575","AMDW","LU0127658192.USD","IE00B5949003.HKD","IE0004445239.USD","LU2264538146.SGD","LU0081259029.USD","LU1803068979.SGD","LU1064131342.USD","BK4588","LU0056508442.USD","BK4573","DAMD","BK4605","LU2360106780.USD","LU0198837287.USD","LU1989764664.SGD","LU0274383776.USD","AMYY","BK4585","AMDY","LU1880398554.USD","BK4604","LU2250418816.HKD","LU0082616367.USD","LU0390134368.USD","BK4099","LU1242518931.SGD","IE0009356076.USD","LU1303367103.USD","LU0642271901.SGD","LU1880398471.USD","FDMT","LU1988902786.USD","AMDG","LU2931357623.SGD","LU2098885051.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":10,"totalSize":200,"code":"91000000","status":"200"}]}}